Conditions

GLP-1 and Psoriasis: What Dermatologists Are Observing

GLP-1 Companion · 8 min read

Dermatologists are increasingly encountering a pattern: patients with chronic plaque psoriasis who start GLP-1 medications for weight management or type 2 diabetes return to clinic reporting marked skin improvement — sometimes beyond what their dermatologic therapy alone had achieved. This is not entirely surprising to those who understand the inflammatory biology connecting psoriasis and obesity, but the magnitude and consistency of reports has moved the topic from anecdote toward active clinical investigation.

The Psoriasis–Obesity–Inflammation Connection

Psoriasis is a systemic inflammatory disease, not merely a skin condition. It involves dysregulation of the Th17/Th1 immune axis, with overproduction of interleukins IL-17A, IL-23, and TNF-α. These cytokines drive the characteristic keratinocyte hyperproliferation and dermal infiltration of the disease — but they also circulate systemically and contribute to metabolic dysfunction.

Obesity amplifies this inflammatory milieu. Visceral adipose tissue acts as an endocrine organ secreting pro-inflammatory adipokines — leptin, resistin, and visfatin — that synergize with psoriatic cytokines. Adiponectin, an anti-inflammatory adipokine that is paradoxically reduced in obesity, is inversely correlated with psoriasis severity. The result is a bidirectional relationship: psoriasis worsens metabolic inflammation, and obesity worsens psoriatic inflammation.

• People with psoriasis have a 1.5–2.0 times higher risk of developing obesity compared to the general population.
• Among people with obesity, the risk of developing psoriasis is approximately 1.4 times the population baseline.
• Psoriasis Area and Severity Index (PASI) scores are significantly correlated with BMI in observational studies.
• Weight loss of as little as 5% of body weight has been associated with improvements in PASI in small clinical trials.

Case Reports and Observational Data

The earliest systematic reports of psoriasis improvement on GLP-1 therapy came from diabetology clinics where patients with concurrent psoriasis were initiated on liraglutide or semaglutide for glycemic control. A 2021 case series published in the Journal of the European Academy of Dermatology and Venereology described five patients with moderate-to-severe plaque psoriasis who experienced PASI reductions of 40–70% after 16–24 weeks of semaglutide therapy, without any change in their dermatologic regimen.

A retrospective analysis of 127 patients with psoriasis who received GLP-1 therapy (primarily semaglutide or liraglutide) for at least 6 months, published in 2023, found that 61% reported subjective improvement in skin symptoms, and among those with documented PASI scores, the mean reduction was 34%. The confounding effect of concurrent weight loss could not be fully separated from direct GLP-1 effects in this analysis.

Anti-Inflammatory Mechanisms of GLP-1 Receptors

Beyond weight loss, GLP-1 receptor agonists appear to exert direct anti-inflammatory effects through GLP-1 receptor signaling in immune cells and tissues. GLP-1 receptors are expressed on macrophages, dendritic cells, T-lymphocytes, and keratinocytes. Activation of these receptors has been shown in preclinical models to:

• Suppress NF-κB signaling, a master inflammatory transcription factor downstream of TNF-α and IL-1β.
• Reduce macrophage polarization toward the M1 (pro-inflammatory) phenotype and promote M2 (anti-inflammatory) macrophage activity.
• Decrease production of IL-6, IL-1β, and TNF-α in stimulated macrophages in vitro.
• Upregulate anti-inflammatory adiponectin, which is typically suppressed in obesity and associated with psoriasis severity.
• Modulate keratinocyte proliferation and differentiation in cell culture models relevant to psoriatic pathology.

The anti-inflammatory effects of GLP-1 receptor agonists appear to operate through at least two independent pathways: indirectly through adipose tissue reduction and insulin sensitization, and directly through GLP-1 receptor signaling in immune and skin cells. Disentangling these contributions requires randomized controlled trials with weight-matched controls.

Retatrutide and Psoriasis: Emerging Triple Agonist Data

Retatrutide — a triple GIP/GLP-1/glucagon receptor agonist in Phase 3 development as of early 2026 — has generated particular interest in the dermatology community. Phase 2 MAGNITUDE trial data published in 2023 showed that retatrutide produced mean weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks, exceeding that of approved GLP-1 agents in comparable populations.

Within the Phase 2 cohort, a subset analysis of the 14 participants with documented psoriasis at baseline (PASI ≥3) found that 9 of 14 (64%) experienced PASI reductions of more than 50% by week 24. While the sample size is far too small to draw firm conclusions, the observation has prompted a planned psoriasis substudy within the Phase 3 retatrutide program. Glucagon receptor activation — unique to retatrutide among approved or near-approval agents — may provide additional anti-inflammatory effects relevant to psoriatic disease, though this remains speculative.

What to Realistically Expect

Patients with psoriasis who start GLP-1 therapy for weight or metabolic indications should not expect GLP-1 medications to replace biologic therapies for moderate-to-severe disease. The anti-psoriatic effect, where it occurs, appears to be:

• Proportional to the degree of weight loss — patients who lose 10% or more of body weight see the most skin benefit.
• More pronounced in patients with predominantly obesity-driven psoriasis flares rather than immune-driven disease independent of weight.
• Incremental to — not a substitute for — biologic or conventional systemic therapy in moderate-to-severe disease.
• Potentially enabling in mild-to-moderate psoriasis, where GLP-1-driven weight loss may be sufficient to achieve PASI 75 without additional systemic therapy.

Limitations of Current Evidence

The current evidence base for GLP-1 and psoriasis has significant limitations that must be acknowledged:

• No randomized controlled trial has been specifically designed and powered to evaluate a GLP-1 agent as a psoriasis treatment with psoriasis outcomes as a primary endpoint.
• Observational studies cannot separate the effect of weight loss from a direct GLP-1 anti-inflammatory effect — both are occurring simultaneously.
• Publication bias may favor reporting positive skin outcomes while negative or null cases go unreported.
• Most data come from patients on semaglutide or liraglutide; tirzepatide and retatrutide data are far more limited.
• Long-term durability of psoriasis improvement on GLP-1 therapy has not been studied.

The Bottom Line

The convergence of psoriasis and obesity biology makes GLP-1-mediated skin improvement mechanistically plausible, and the accumulating case reports and observational data are compelling enough to justify formal clinical trials. For patients with both conditions, GLP-1 therapy may be particularly well-suited — simultaneously addressing the metabolic and inflammatory drivers of their disease. The evidence is not yet strong enough to position GLP-1 as a dermatologic treatment, but it is strong enough to make psoriasis an active area of GLP-1 research in 2026 and beyond.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.